Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174282
Title: European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain
Author: Caldas, María
Pérez Aisa, Ángeles
Castro Fernández, Manuel
Bujanda, Luis
Lucendo, Alfredo
Rodrigo, Luis
Huguet, Jose
Pérez Lasala, Jorge
Molina Infante, Javier
Barrio, Jesús
Fernández Salazar, Luis
Lanas, Ángel
Perona, Mónica
Domínguez Cajal, Manuel
Ortuño, Juan
Gómez Rodríguez, Blas
Almela, Pedro
Botargués, Josep María
Núñez, Óscar
Modolell, Inés
Gómez, Judith
Ruiz Zorrilla, Rafael
Coba, Cristóbal De La
Huerta, Alain
Iyo, Eduardo
Pozzati, Liliana
Antón, Rosario
Barenys de Lacha, Mercé
Angueira, Teresa
Fernández Bermejo, Miguel
Campillo, Ana
Alcedo, Javier
Pajares Villaroya, Ramón
Mego, Marianela
Bermejo, Fernando
Domínguez Jiménez, José
Titó, Llúcia
Fernández, Nuria
Pabón Carrasco, Manuel
Cosme, Ángel
Mata Romero, Pilar
Alcaide, Noelia
Ariño, Inés
Maira, Tommaso Di
Garre, Ana
Puig, Ignasi
Nyssen, Olga
Megraud, Francis
O’Morain, Colm
Gisbert, Javier
Keywords: Infeccions per Helicobacter pylori
Terapèutica
Helicobacter pylori infections
Therapeutics
Issue Date: 25-Dec-2020
Publisher: MDPI
Abstract: The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain.
Note: Reproducció del document publicat a: https://doi.org/10.3390/antibiotics10010013
It is part of: Antibiotics, 2020, vol. 10, num. 1
URI: http://hdl.handle.net/2445/174282
Related resource: https://doi.org/10.3390/antibiotics10010013
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
antibiotics-10-00013-v2.pdf909.61 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons